跳至主要内容
临床试验/jRCT1031250136
jRCT1031250136招募中不适用

Prospective, observational study of the impact of efanesoctocog alfa (ALTUVIIIO) on goal attainment and physical activity in people with moderate or severe Hemophilia A (ACTIVIIITY)

Sanofi Aventis Recherche & Developpement0 个研究点目标入组 35 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
35
主要终点
Proportion of total goals achieved at quarterly timepoints and EoS

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
12age old over 至 50age old under(—)

入选标准

  • Signed and dated informed consent form (ICF) by the patient, or the patients legally authorized representative(s) for patients under the legal age, before any study-related activities are undertaken. Assent should be obtained from pediatric patients according to local institutional/ institutional review board (IRB) regulations
  • At enrollment, newly starting prophylaxis therapy with efa according to usual clinical practice, with efa initiated within 6 months after the enrollment visit.
  • Diagnosis of moderate (endogenous FVIII activity between 1% to 5% of normal) or severe (endogenous FVIII activity <1% of normal) hemophilia A
  • Aged 12 to 50 years at time of enrollment, inclusive.
  • Access to a smartphone device (Android version 12.0 or higher; or iOS 13 or higher) with Bluetooth 4.0 (minimum) or 5.0 (recommended) capabilities for compatibility with physical activity tracker.
  • Availability of home-based access to internet for electronic patient-reported outcome (ePRO)/diary assessments.
  • Willingness to utilize the ActiGraph LEAP provisional device.

排除标准

  • Enrollment in another concurrent interventional clinical study, or intake of an investigational medicinal product within 3 months prior to inclusion in this study.
  • Current diagnosis of a FVIII inhibitor, defined as inhibitor titer >=0.60 BU/mL.
  • Use of efa for prophylaxis in the 6 months prior to enrollment.

结局指标

主要结局

Proportion of total goals achieved at quarterly timepoints and EoS

时间窗: quarterly timepoints and EoS

Proportion of total goals achieved at quarterly timepoints and EoS

Overall physical activity goals (categories/type) ranked by frequency of selection

Overall physical activity goals (categories/type) ranked by frequency of selection

Monthly average of daily step count, activity count, MET, MVPA, intensity gradient (intercept and slope)

时间窗: monthly

Monthly average of daily step count, activity count, MET, MVPA, intensity gradient (intercept and slope)

Monthly average of weekly intensity gradient (intercept and slope)

时间窗: monthly

Monthly average of weekly intensity gradient (intercept and slope)

Proportion of patients who reached a +2 or +1 on at least one goal at quarterly timepoints and EoS

时间窗: quarterly timepoints and EoS

Proportion of patients who reached a +2 or +1 on at least one goal at quarterly timepoints and EoS

Overall GAS score quarterly and at EoS

时间窗: quarterly and at EoS

Overall GAS score quarterly and at EoS

次要结局

  • Change from baseline in PROMIS Pain intensity score
  • Change from baseline in HAL score
  • Change from baseline in PROMIS pediatric pain intensity score
  • Change from baseline in PedHAL score
  • Change from baseline in school/work hours missed as assessed by WPAI+CIQ:HS
  • Change from baseline in productivity as assessed by WPAI+CIQ:HS
  • Change from baseline in impact on other activities as assessed by WPAI+CIQ:HS
  • Mean change from baseline in total and joint domain scores of HJHS
  • Monthly total and average of daily time spent in different intensity levels (sedentary behavior, light intensity, moderate intensity, and vigorous intensity)
  • Monthly average of weekly power law exponent alpha
  • Monthly average of daily median activity count overall, among moderate activities, and among vigorous activities
  • Monthly average of daily median MET overall, among moderate activities, and among vigorous activities
  • Monthly average of median bout length and percent of time of bout length > median bout length for each intensity level (sedentary behavior, light intensity, moderate intensity, and vigorous intensity)
  • Monthly average of weekly 80th, 90th, 95th, and 100th percentiles of activity count and MET
  • Monthly total step count, activity count, MET, MVPA
  • Weekly average of daily step count, activity count, MET, MVPA, intensity gradient (intercept and slope)
  • Weekly intensity gradient (intercept and slope)
  • Total AEs, proportion of patients with at least one AE, and average number of AEs per patient
  • Total SAEs, proportion of patients with at least one SAE, and average number of SAEs per patient
  • Total AESIs, proportion of patients with at least one AESI, and average number of AESIs per patient
  • Number of AEs, SAEs, and AESIs related to efa
  • Proportion of total planned doses that were missed
  • Average time between treatment dose and physical activity
  • Number of patients with no reported bleeds requiring treatment
  • Average number of per patient treatment doses administered for treatment of bleeds

研究者

发起方
Sanofi Aventis Recherche & Developpement

相似试验